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Objective: To compare the efficacy and safety of two different doses of levofloxacin with amoxycillintclavulanic acid 
in the treatment of community-acquired pneumonia. 
Mathod.: A double-blind, randomized (l:l:l), double-dummy, three-arm parallel design, multicenter study was 
conducted in adult patients with mild-to-moderate community-acquired pneumonia. In total, 518 patients were 
randomized to receive levofloxacin 500 mg once daily, levofloxacin 500 mg twice daily or amoxycillin/clavulanic acid 
625 mg three times daily for 7-10 days. 
M u b  The clinical cure rates post-therapy (2-5 days after the end of treatment) in the intent-to-treat population were 
84.2% (1441171) in the levofloxacin oncedaily group, 80.2% (142/177) in the levofloxacin twicedaily group and 85.7% 
(1W168) in the amoxycillin/clavulanic acid group. In the per-protocol population, the clinical cure rates post-therapy 
were 95.2% (138/145), 93.8% (137/146) and 95.3% (141/148), respectively. The total pathogen eradication rates were 
97.896, 10W0 and 97.546, respectively. Both drugs were equally well tolerated and no major adverse events were 
observed. 
Conclusions: Levofloxacin was effective, safe and well tolerated in the treatment of mild-to-moderate community- 
acquired pneumonia. A complementary analysis indicated that there was no difference in therapeutic outcome between 
levofloxacin 500 mg once daily and twice daily. Levofloxacin 500 mg once daily, for 7-10 days, is an effective and safe 
treatment for mild-to-moderate community-acquired pneumonia in adults. 
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INlRODUCTlON 
Community-acquired pneumonia (CAP) is an acute 
lower respiratory tract illness which is usually associated 
with fmer, focal signs and symptoms in the chest and 
recent pulmonary infiltrate in the chest X-ray [1,2]. 
The occurrence of CAP is influenced by geographic 
and seasonal factors as well as population variables such 
as age and the presence of underlying disease(s). Despite 
the availability of modern antibacterial agents and a 
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slow decrease in the mortality rate over the last five 
decades, it remains a common and serious disease and 
is the fifth or sixth leading cause of death in counties 
such as the USA, the UK and Sweden. 
Although the etiology of CAP continues to be 
investigated, it is generally agreed that Streptococnrs 
pneumoniue is the most common cause, accounting 
for 30-70% of cases [3-7]. Other common pathogens 
include Huemophilus infuenzue (2-18% of cases), 
Mytoplusmu spp. (2-24%), Chtamydiu spp. (1-3%), 
Legionella spp. (1-15%), S t i z p h y l o m  u u m  (1-lo%), 
Moraxella caturrhulis (1-5%), Streptocouxcs spp. (l-3%), 
Gram-negative bacilli such as Escherkhiu coli, Mebsiellu 
spp. and Pseudomonus spp. (1-1 0%) and viruses (1-2 1 %) . 
Up to 100? of cases may be due to two or more aerobic 
bacteria, with Streptococcus pneumonia and H. i n f m a e  
being the most common combination [5,8,9]. 
The choice of initial antibacterial agent is usually 
empirical, and it should be filly effective against 
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Streptococcus pneumoniae and other common pathogens, 
including the atypical, intracellular pathogens Myco- 
plasma and Chlamydia. The worldwide emergence of 
Streptococcus pneumoniae with reduced susceptibility or 
resistance to penicillin and macrolides, combined with 
the resistance problems associated with p-lactamase- 
producing H.  injuenzae and Moraxella catarrhalis, has 
provided a therapeutic challenge [lo-121. Penicillin- 
resistant pneumococci are ofien also resistant to 
macrolides and azalides. In addition, atypical pathogens 
are not susceptible to p-lactam antibiotics, and their 
susceptibility to macrolides is variable. The intro- 
duction of new antibiotics may simplify the initial 
treatment of CAP through broader coverage of 
potential pathogens and possibly by shortening the 
course of therapy. 
Levofloxacin is the L-isomer of the racemate 
ofloxacin and is approximately twice as active as the 
equivalent amount of ofloxacin in vitro [13]. It has 
a broad spectrum of activity which includes Gram- 
positive aerobic bacteria such as Streptococcus pneumoniae 
and Staphylococcus aureus, Gram-negative bacteria such 
as Escherichia coli, H .  inzuenzae, Klebsiella spp. and 
Pseudornonas aeruginosa, and atypical bacteria such as 
Chlamydia pneumoniae, Mycoplasma pneumoniae and 
Legionella pneurnophila [13-151. Oral levofloxacin is 
rapidly absorbed with 100% bioavailability, and peak 
plasma concentrations are reached within 1 h. It is 
eliminated relatively slowly, primarily by the kidneys, 
with a half-life of 6-8 h, allowing once-daily dosing 
[ 16,171. 
The spectrum of activity of levofloxacin, combined 
with its good penetration into lung tissue and bronchial 
secretions [18-201 and previous clinical studies [21-241, 
indicates that it may be effective in CAP. The aim of 
this study was therefore to compare the efficacy and 
safety of levofloxacin, at two different doses, with that 
of amoxycillin/clavulanic acid in the treatment of CAP 
in adults. Amoxycillin/clavulanic acid was chosen as 
the comparator because it is widely used for this 
indication and its efficacy is well documented [25-271. 
PATIENTS AND METHODS 
Study design 
This was a double-blind, randomized (l:l:l), double- 
dummy, three-arm parallel design, multinational, multi- 
center study conducted in 50 centers in nine countries 
in patients with mild-to-moderate pneumonia. Patients 
were randomized to receive levofloxacin 500 mg once 
My, levofloxacin 500 mg twice daily or amoxycillin/ 
clavulanic acid 625 mg three times daily for 7-10 
days. Randomization was made in blocks of six, and 
the study drug was randomly assigned to the patient 
numbers in advance within each block. The primary 
analysis was the cltnical cure rate, determined 2-5 days 
after the end of treatment (post-therapy), in patients 
evaluable for clinical efficacy in the per-protocol 
population. The clinical and bacteriologic efficacy 
assessments, performed by the investigator and a 
computerized evaluation program (per-protocol assess- 
ment), were included in the efficacy analysis. The 
primary analysis was the per-protocol analysis deter- 
mined by computer, and an intent-to-treat analysis was 
also performed. The study was conducted in accor- 
dance with the Good Clinical Practice Guidelines of 
the European Community and The Declaration of 
Helsinki. 
Patients 
In- or outpatients of either sex, aged 18-65 years, with 
clinical signs and symptoms of mild-to-moderate 
pneumonia and physical examination findings consistent 
with the clinical diagnosis were included in the study. 
Chest X-ray results confirming the clinical diagnosis of 
pneumonia had to be present. Patients were excluded 
if they were pregnant or of childbearing potential and 
not taking adequate contraceptive measures or if they 
had pneumonia occurring more than 72 h after 
hospitalization; pneumonia requiring parenteral anti- 
biotic treatment; one or more indicators of severe 
pneumonia; pneumonia expected to be a terminal 
event; glucose-6-phosphate deficiency; hypersensitivity 
to ofloxacin or other fluoroquinolones or penicillin/ 
p-lactams; or any concomitant clinical condition likely 
to interfere with the conduct of the study. Patients were 
also excluded if they: required parenteral antibiotic 
treatment for pneumonia; had received ofloxacin or 
amoxycillin/cladanic acid for this infectious episode; 
required probenecid or maintenance systemic corti- 
costeroid therapy or a systemic antibiotic for another 
infection; or had received antibiotic pretreatment for 
more than 24 h in the 5 days before study entry or 
azithromycin in the 7 days before study entry. All 
patients provided written informed consent and the 
study protocol was approved by each local ethics 
committee. 
Clinical 
Assessments were performed after 3 and 6 days of 
treatment, and 2-5 (post-therapy) and 14-21 days after 
the end of treatment. Clinical signs and symptoms of 
pneumonia were documented at each visit. The clinical 
response was defined as follows: cure (all infection signs 
and symptoms disappeared or returned to preinfection 
state and chest X-ray improved, or at least one 
infection-related sign and symptom, including chest X- 
ray, improved and no subsequent antibiotic treatment 
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started); failure (all infection-related symptoms un- 
changed or worsened; new clinical findings developed 
consistent with active infection; death due to pneu- 
monia; study drug discontinued because of clinical 
and/or bacteriologic treatment failure; one or more 
antibiotics added to the study drug because of 
treatment failure or at least one infection-related sign 
and symptom, including chest X-ray, improved but 
subsequent antibiotic treatment started) or indeter- 
minate (circumstances precluded classification as cure 
or failure, e.g. missing follow-up information, pre- 
mature discontinuation because of non-efficacy-related 
reasons, major protocol violations). Patients were 
withdrawn and switched to another antibiotic regimen 
if: the clinical response was classed as failure after at least 
48 h of treatment; the bacteriologic response was 
unsatisfactory; or serious adverse events occurred 
which were possibly related to study drug. 
Bacteriologic 
Bacteriologic cultures were obtained firom respiratory 
tract secretions and blood samples within 48 h before 
the start of treatment in order to isolate and identify the 
causative pathogen. The majority of respiratory tract 
cultures were obtained fiom non-invasive samples, 
e.g. sputum, although some were obtained by inwive 
methods such as bronchoscopic brushings, transtracheal 
aspiration and bronchoalveolar lavage. Follow-up 
cultures were obtained on day 3 in patients who had 
not responded clinically, on day 6 in the case of drug 
failure, 2-5 days after the end of treatment and 14-21 
days &er the end of treatment in the case of failure. 
Blood cultures were repeated in patients with persistent 
fever. Serum samples were also obtained at inclusion 
and 14-21 days after treatment for the determination 
of antibody titer to Mycoplasma pneumoniae, Chlamydia, 
Legionella and influenza viruses A and B. 
The bacteriologic response was defined as: satis- 
factory (eradication of baseline pathogen; presumed 
eradication; colonization), unsatisfactory (persistence 
of baseline causative pathogen; relapse; superinfection; 
eradication and reinfection; new or additional anti- 
biotic because of presumed persistence or resistance), 
or indeterminate (lack of opportunity to perform 
further cultures). If more than one causative pathogen 
was isolated h m  the pretreatment culture and the 
microbiological response was not the same for all the 
pathogens, the patient was classed as unsatisfactory if 
the response of at least one pathogen was unsatisfactory. 
safay 
Safety was assessed at each visit accordmg to adverse 
events and laboratory variables. Adverse events were 
assessed by the investigator for intensity (mild, moderate 
or severe), nature (serious or non-serious) and possible 
relationship to the study drug. Patients were withdrawn 
h m  the study immediately in the case of a serious 
adverse event possibly related to the study drug. 
Statistical analyses 
Analyses were performed on the responses in the 
intent-to-treat population, the per-protocol population 
and a l l  patients with clinical signs and symptoms of 
infection excluding major protocol violators. The 
primary efficacy variable was the clinical cure rate, 
post-therapy (determined 2-5 days after the end of 
treatment), in the per-protocol population. Assuming a 
success rate of 80% in all the treatment groups and a 6 
of 15% (the maximum Merence between the two 
levofloxacin groups and the amoxycillin/clavulanic acid 
group to be accepted as equivalent), 125 evaluable 
patients per group were required to provide an 80% 
chance @ower=80%) of having a successfid trial, 
defined as that producing a two-sided 95% confidence 
interval (CI) for the difFerence between the clinical cure 
rates of the two treatments that excluded the pre- 
specified 6 value of 15% [28-301. Each lmfloxacin 
group was considered to be equivalent to the amoxy- 
cillin/clavulanic acid group if the upper and lower 
bounds of the 95% CI for the efficacy rate difference 
were >Ct% and > - 15%, respectively. A comparison 
between the two levofloxacin groups was also per- 
formed as a complementary analysis, using the same 
rule as above. 
In total, 1411 patients were screened, of whom 518 
were included in the study, h m  50 centers in nine 
countries. Two patients were withdrawn at their own 
request before the study drug was administered, so 516 
patients were included in the intent-to-treat popu- 
lation. The demographic and baseline characteristics of 
the intent-to-treat population are shown in Table 1. 
The only statistically significant Merence between the 
groups was a higher proportion of men in the 
amoxycillin/cladanic acid group than in the lam- 
floxacin twice-daily group (67.9% versus 57.6%; 
p=0.05). This Merence was accounted for in the 
efficacy analysis of robustness. 
At inclusion, 297 (57.6%) patients had con- 
comitant illnesses in the form of underlying diseases, of 
which the most tiequent were respiratory, other than 
pneumonia. Surgical history was positive in 171 
patients (33.1%), and a history of drug/alcohol abuse 
and smoking was observed in 14 (2.7%) and 295 
(57.2%) patients, respectively. One hundred and four 
(20.2%) patients were receiving concomitant non-anti- 
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Table 1 Demographic characteristics (intent-to-treat population) 
Amoxycillin/ 
Levofloxacin Levofloxacin clavulanic acid 
1X5OO mg 2x500 mg 3x625 mg 
(n=171) (n=177) (tt=168) 
Mean (+SD) age (years) 41.19k15.78 40.96214.20 40.93k14.23 
Male 101 (59.1%) 102 (57.6%) 114 (67.9%) 
Female 70 (40.9%) 75 (42.4%) 54 (32.1%) 
Mean (kSD) weight (kg) 68.362 14.99 66.76213.46 66.85k12.51 
Race 
whlte 130 (76.0%) 131 (74.0%) 124 (73.8%) 
Black 25 (14.6%) 30 (16.9%) 
Other 15 (8.8%) 15 (8.5%) 15 (8.9%) 
Mean BMI in kg/rnZkSD 24.4624.82 23.68k3.97 23.4023.83 
Diagnosis 
Lobar pneumonia 140 (81.9%) 141 (79.7%) 131 (78.0%) 
Bronchopneumonia 27 (15.8%) 29 (16.4%) 29 (17.3%) 
Other 4 (2.3%) 7 (4.0%) 8 (4.8%) 
Mild 82 (48.0%) 86 (48.6%) 87 (51.8%) 
Moderate 89 (52.WA) 91 (51.4%) 81 (48.2%) 
Good 131 (76.6%) 137 (77.4%) 134 (79.8%) 
29 (17.3%) . 
Asian 1 (0.6%) 1 (0.6%) 0 
Severity 
General condition 
Poor 39 (22.8%) 39 (22.0%) 34 (20.2%) 
Critical 1 (0.6%) 1 (0.6%) 0 
infective medication. Prior antibiotic treatment occur- 
red in 54 (10.5%) patients. During treatment, 218 
(42.2%) patients received concomitant non-anti- 
infective medications. 
At inclusion, 370 patients were assigned to 7 days' 
treatment and 148 to 10 days' treatment. The treatment 
duration was prolonged to 10 days on day 6 in 72 
patients originally assigned to 7 days' treatment. The 
mean treatment duration was 8.1 days in all three 
groups. Treatment was discontinued prematurely in 37 
(7.2%) patients (1 1 in the levofloxacin once-daily group, 
16 in the levofloxacin twice-daily group and 10 in the 
amoxycillin/clavulanic acid group). One hundred and 
five major protocol violations occurred in 75 patients 
in the intent-to-treat population, giving a per-protocol 
population of 441. No causative pathogen was isolated 
in 321 patients, so bacteriologic efficacy was assessed in 
120 patients. The number of patients included in each 
analysis is shown in Table 2. 
Clinical efficacy 
The clinical cure rates are shown in Table 3. In 
the intent-to-treat population post-therapy, the two- 
sided 95% CI for the differences in cure rates revealed 
therapeutic equivalence between amoxy&in/clavu- 
lanic acid and the levofloxacin once-My (-9.7%; 
+6.7%) and twice-daily groups (-14.0%; +3.0%). 
The clinical response in the per-protocol population 
post-therapy as assessed by the computerized evaluation 
program was the primary efficacy outcome measure. 
The two-sided 95% CI for the differences in cure rates 
also revealed therapeutic equivalence between amoxy- 
cillin/clavulanic acid and the levofloxacin once-daily 
group (-5.7%; +5.5%) and the levofloxacin twice- 
dady group (-7.3%; +4.4%). A complementary 
analysis comparing the two levo%oxacin groups did not 
show any difference. Of the 23 patients classed as 
failures, 14 improved with subsequent antibiotic. 
In the per-protocol population with bacterio- 
logically proven infection, the two-sided 95% CI for 
the Serences in cure rates also revealed therapeutic 
equivalence between amoxycillin/clavulanic acid and 
the levofloxacin once-daily group (- 12.2%; + 13.6%) 
and the levofloxacin twice-daily group (-14.1%; 
+ 1 2.2%). 
The clinical response post-therapy in all three 
populations, as assessed by the investigator, supported 
the findings of the computerized evaluation program. 
In the intent-to-treat population, the clinical cure rates 
were 90.6%, 87.6% and 91.1% in the levofloxacin 
once-daily, levofloxacin twice-daily and amoxycillin/ 
clavulanic acid groups, respectively. In the per-protocol 
population, the clinical cure rates were 95.9%, 95.2% 
and 96.0%, respectively. The corresponding 95% CI 
values for levofloxacin once daily versus amoxy- 
cillin/clavulanic acid and levofloxacin twice daily 
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Table 2 Number of Datients included in each anal* 
~~~ ~~ 
Amaxycillid 
Levoflcaacin LCvOflaXaCin clavulanic acid 
1x500 mg 2x500 mg 3x625 mg Total 
Patients enrolled 172 177 169 518 
Withdrawn fium the study 
Intent-*treat 171 177 168 516 
Excluded fium per-protocol 
before start of study drug 1 0 1 2 
d Y =  26 30 19 75 
Per-protocol 145 147 149 441 
p m n  infection 40 45 35 120 
No pathogen isolated 105 102 114 321 
Per-protocol+ bacteriologically 
Table 3 Clinical response post-therapy 
Number of patients (%) 
Ammcydllin/ 
LWOflaXaCin LwOflOXaCin davuLnic acid 
Population Assessnent 1X500mg 2x500 rng 3 x 6 s  mg 
Intention-to-treat No. of patients 171 177 168 
CurC 144 (84.2%) 142 (80.290) 144 (85.7%) 
Fail- 27 (15.8%) 35 (19.8%) 24 (14.3%) 
Per-protocol No. of patients 145 147 149 
Indeterminate 0 1 1 
Total analyzed 145 (100%) 146 ( l W o )  148 (100%) 
FdurC 7 (4.8%) 9 (6.Wo) 7 (4.7%) 
Cure 138 (95.2%) 137 (93.8%) 141 (95.3%) 
BacteriologicaUy proven infection No. of patients 40 45 35 
CurC 38 (95.0%) 42 (93.3%) 33 (94.3%) 
Fail- 2 (5.0%) 3 (6.7%) 2 (5.7%) 
95% CIS arc given in the results. 
versus amoxycillin/clavulanic acid were -5.3% and 
+5.1%, and -6.1% and +4.6%, respectively, indicating 
therapeutic equivalence. In the per-protocol popu- 
lation with bacteriologically proven infection, the cure 
rates were 97.5%, 93.3% and 97.1%, respectively. 
Evaluation of the clinical response performed at the end 
of the study (14-42 days after the end of treatment) also 
revealed no differences between the three treatment 
groups. Efficacy evaluations in subgroups of patients 
(presumed pneumococcd pneumonia; fever at baseline; 
lobar pneumonia; and smokers) revealed similar 
findings to the main analysis. 
Bacteriologic efficacy 
The pathogens isolated at inclusion are shown in Table 
4. The majority of respiratory tract cultures were 
obtained fiom non-invasive samples; only 4.4% of 
patients (61136) had invasive samples (two in the 
levofloxacin once-daily group, three in the levofloxacin 
twice-daily group and one in the amoxycillin/ 
clavulanic acid group). Bacteremia was found in 2.3% 
(1/43) of levofloxacin once-daily patients, 19.6% 
(10/51) of levofloxacin twice-daily patients and 16.7% 
(7/42) of amoxycillin/clavulanic acid patients. A single 
pathogen was isolated in 113 patients, two pathogens 
in 21 patients and three pathogens in two patients. A 
four-fold increase in serum antibody titer between the 
acute and convalescent serum for atypical infections 
was observed in 5.8% (16/274) of patients (Mycoplarma 
pneumoniae eight patients, Chlamydia two, Legionella 
one, influenza A one and influenza B four). 
More pathogens, both Gram-positive and Gram- 
negative, were resistant to amoxycillin/clavulanic acid 
than to levofloxacin. At inclusion, using the disk 
diffusion method, only one (Streptococcus pneumoniae) of 
the 156 (0.6%) isolated pathogens tested was mistant 
to levofloxacin, while 14 of 138 (10.1%) pathogens 
tested (three Gram-positive and 11 Gram-negative (five 
enterobacteria and six non-enterobacteria)) were 
resistant to amoxycillin/clavulanic acid. None of the 
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Table 4 Causative pathogens isolated at inclusion in the intent-to-treat population 
Pathogen 
AmOXy&/ 
Levofloxacin Levofloxacin davulanic acid 
1X500mg 2x500 mg 3x625 mg Total 
StreptouKncs pneumoniae 
Haemophilus inauenzae 
StqhylouKncs aureus 
H. parainzuenzae 
Moraxella catanhalis 
Klebsiella pncumoniae 
Pseudomonas amginosa 
Enterobacter cloacae 
Pmteus mirabilis 
Klebsiella orytoca 
Streptocorn viridans 
16 
21 
2 
3 
2 
3 
1 
2 
0 
1 
0 
28 
17 
3 
6 
3 
1 
1 
1 
1 
0 
0 
19 
17 
6 
1 
3 
0 
1 
0 
1 
0 
1 
63 (39.1%) 
55 (34.2%) 
11 (6.8%) 
10 (6.2%) 
4 (2.5%) 
8 (5.0%) 
3 (1.9%) 
3 (1.9%) 
2 (1.2%) 
1 (0.6%) 
1 (0.6%) 
Total 51 61 49 161 
Table 5 Bacteriologic response in the per-protocol + bacteriologically proven infection population post-therapy 
AmoXycillin/ 
Levofioxacin Levofloxacin clavulanic acid 
1X500me 2x500 me 3x625 me Total 
Total treated 
Indeterminate 
Satisfactory-ut of time window 
Total analyzed 
Satisfactory 
Eradication 
Presumed eradication 
Unsatisfactory 
Persistence 
Presumed persistence 
40 
1 
0 
39 (100%) 
37 (94.9%) 
34 . 
3 
2 (5.1%) 
1 
1 
45 
1 
1 
43 (100%) 
43 (100%) 
7 
36 
0 
35 
0 
1 
34 (100%) 
32 (94.1%) 
4 
28 
1 
0 
2 (5.9%) 
120 
2 
2 
116 
112 
14 
98 
4 
2 
1 
Eradication+superinfection 0 1 1 
Table 6 Bacteriologic eradication rate by pathogen in the per-protocol+bacteriologically proven infection population post- 
theravv 
Lmfloxacin 
1 X500 mg 
Levofloxacin 
2x500 m g  
Amoxycillin/ 
clavulanic acid 
3x625 mg 
Total pathogens 
Gram-negative 
Pseudomom amginosa 
Moraxella catarrhalis 
Haemophifus injuenzae 
H .  parainauenzae 
Other 
Sraphylocoms aureus 
Sfreptormus pneumoniae 
0th- 
Gram-positive 
44/45 (97.8%) 
28/29 (97%) 
1/1 
2/2 
19/19 
2/3 
4/4 
16/16 (lW?) 
1/1 
15/15 
- 
53/53 (100%) 
28/28 (100%) 
1/1 
2/2 
16/16 
6/6 
3/3 
25/25 (100%) 
313 
22/22 
39/40 (97.5%) 
16/17 (94.1%) 
1/1 
1 /2 
12/12 
1/1 
111 
23/23 (100%) 
6/6 
16/16 
1/1 
isolates from the levofloxacin once-daily group (0/51) 
and one of the 59 isolates (1.7%) h m  the twice-daily 
group was resistant to levofloxacin, while five of 40 
isolates (12.5%) from the amoxycillidclavulanic acid 
group were resistant to amoxycillin/clavulanic acid. 
The bacteriologic response post-therapy in the 
per-protocol population with bacteriologically proven 
infection as assessed by the computerized evaluation 
program is shown in Table 5. All three groups showed 
a similar bacteriologic response rate. Similar findings 
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were observed in the investigator’s assessment of 
bacteriologic response (levofloxacin once daily 95.0%, 
levofloxacin twice daily 95.6%, amoxycillin/clavulanic 
acid 94.3%). The bacteriologic eradication rate by 
pathogen at post-&erapy is shown in Table 6. All Gram- 
positive isolates (Streptococcus pneumoniae, Stapkylocorcus 
a u m )  and all H. injuenzae isolates were eradicated by 
all three treatments. Post-therapy, one H. parainzuenzae 
isolate &om a multipathogen infection in a patient in 
the levofloxacin once-daily group and one Moraxella 
catawhalis isolate in a patient in the amoxycillin/ 
clavulanic acid group persisted. The only pathogen 
which was resistant to levofioxacin in the levofloxacin 
twicedaily group was presumed to be eradicated. 
Evaluation of the bacteriologic response performed at 
the end of the study (14-42 days after the end of 
therapy) also revealed no differences between the three 
treatment groups. 
safety 
All patients included in the intent-to-treat population 
were assessed for safety. The incidence of adverse events 
was similar in all three treatment groups. The incidence 
of adverse effects by body system is shown in Table 7. 
The mjority of adverse events in a l l  three groups were 
mild to moderate in intensity. Five events reported by 
four patients in the levofloxacin once-daily group, four 
events by four patients in the twice-daily group and six 
events reported by five patients in the amoxycillid 
clavulanic acid group were considered by the investi- 
gator to be severe in intensity. 
There was a low or no incidence of adverse events 
associated with the fluoroquinolone class of antibiotics, 
i.e. musculoskeletal, central nervous system, cardio- 
vascular, digestive system, skin rash/phototoxicity and 
eye disorders. The majority of events in all three p u p s  
were mild to moderate in intensity. 
Serious adverse events irrespective of their 
relationship to the study drug were reported by seven 
patients in the levofloxacin once-dady p u p  (4.1%), 11 
in the levofloxacin twice-daily group (6.2%) and six in 
the amoxycillin/clavulanic acid group (3.6%). Serious 
adverse events in 10 of 24 patients were considered to 
be possibly related to the study drug by the investigator 
(four in the levofloxacin once-daily group, four in the 
levofloxacin twice-daily group and two in the 
amoxycillin/clavulanic acid group). 
Two deaths occurred, both in the amoxycillin/ 
clavulanic acid group. One patient died 13 days after 
the end of treatment (due to tuberculosis) and the other 
died 2 h afker the first dose of study drug (due to status 
asthmaticus). Treatment was discontinued in 18 patients 
(3.5%) due to adverse events (five in the levofloxacin 
once-daily group, eight in the levofloxacin twice-daily 
group and five in the amoxycillin/clavulanic acid 
group). There were no clinically relevant abnormalities 
in laboratory parameters. 
DISCUSSION 
The worldwide emergence of resistance to B-laaams 
and macrolides among ,respiratory tract pathogens has 
Table 7 Number of patients with adverse events (AEs) by body system (patients could have more than one AE) 
Number of patien6 (%) 
AUAES Possibly related AEs 
Amqcillin/ AmcaYcillin/ 
h5oxacin Lcvofloxacin clavulanicacid Lcvo5oxacin Lcvofloxaciu clawl?nicacid 
BodYsyJtun 1x500 mg 2x500 mg 3x625 mg 1X500mg 2X500mg 3x625 mg 
Total no. 171 ( l W ? )  177 (100%) 168 (lW!) 171 ( l W ? )  177 (1Wo) 168 (100%) 
Total with AEs 67 (39.24 74 (41.8%) 71 (42.3%) 46 (26.9%) 51 (28.8%) 50 (29.8%) 
Body as whole 11 (6.4%) 7 (4.P?) 6 (3.6%) 6 (3.5%) 1 (0.6%) - 
Cudiovasl-.ukr 4 (2.3%) 7 (4.Ph) 3 (1.8%) - - - 
DigCStiVC 14 (8.2%) 18 (10.2%) 26 (15.5%) 11 (6.4%) 14 (7.9%) 20 (11.9%) 
l p p h ? t i C  
Injection site reaction - 1 (0.6%) - - - - 
Musculcwkeletal - 4 (2.3%) - - 1 (0.6%) - 
Respiratory 15 (8.8%) 7 (4.0%) 17 (10.1%) 4 (2.3%) 1 (0-6%) 2 (1.2%) 
special JensTs 1 (0.6%) 1 (0.6%) - - - - 
Urogmital 5 (299) 4 (2.3%) 4 (2.4%) - 3 (1.7%) 2 (1.2%) 
Hematologic/ 
26 (15.2%) 35 (19.8%) 25 (14.9s’) 23 (13.5%) 30 (16.9%) 21 (12.5%) 
Metabolic and 
nutritional 10 (5.8%) 14 (7.9%) 12 (7,1%) 6 (3.5%) 8 (4.5%) 10 (6.0%) 
NCIVOLYS 3 (1.8%) 4 (2.3%) 1 (0.6%) 2 (1.2%) - 1 (0.6%) 
Skin and appendages 5 (2.9%) 8 (4.5%) 6 (3.6%) 2 (1.299) 4 (2.3%) 3 (1.8%) 
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led to the reassessment of treatment for CAP [8,31]. 
The newer fluoroquinolones, such as levofloxacin and 
grepafloxacin, have good activity against respiratory 
tract pathogens and are well tolerated [13,32]. They 
should, therefore, provide a usefd alternative treatment 
in the face of the increasing spread of resistance to 
traditional antibiotics [33]. 
Sparfloxacin was the first of the newer fluoro- 
quinolones to be introduced but it has been associated 
with a high incidence of photosensitivity reactions and 
cardiovascular adverse events [34]. In studies of CAP, 
sparfloxacin was shown to be as effective as the 
comparators, with overall efficacy rates of 92% and 87% 
compared with 82% for the combination of amoxy- 
cillin and ofloxacin [35], 80% for amoxycillin/ 
clavulanic acid and 85% for erythromycin [36]. 
Previous studies have demonstrated the efficacy of 
levofloxacin in the treatment of CAP [22,23], and the 
results of our double-blind study confirm these 
findings. Our results show that levofloxacin, at a dose 
of 500 mg once or twice daily for 7-10 days, was 
equivalent to amoxycillin/clavulanic acid three times 
daily, in terms of efficacy, tolerability and safety for the 
treatment of mild-to-moderate CAP. The clinical cure 
and bacteriologic response rates with levofloxacin once 
daily (95.2% and 94.9%, respectively) and twice daily 
(93.8% and loo%, respectively) were. equivalent to 
those with amoxycillin/clavulanic acid (95.3% and 
94.1%, respectively) and this was confirmed by the 
two-sided 95% CIS for the differences in cure rates. 
There was no difference in therapeutic outcome between 
levofloxacin 500 mg once daily and twice daily 
Levofloxacin demonstrated good activity against 
Gram-positive pathogens, including Streptococcus pneu- 
moniae, with a 100% eradication rate. This is an 
important consideration, since Streptococcus pneumoniae 
is the commonest cause of CAP and treatment is often 
empirical. Older fluoroquinolones, such as cipro- 
floxacin, have not been beneficial in the treatment of 
respiratory tract infections because of their limited 
activity against Streptococcus pneumoniue [37]. The 
improved Gram-positive activity of levofloxacin is 
therefore an important advance. 
Both levofloxacin and amoxycillin/clavulanic acid 
were well tolerated. The absence of severe cases of 
pneumonia in this study is reflected in the low 
mortality rate (0.4%), with only two deaths. Higher 
mortality rates of 4.5% for sparfloxacin and 2.0% for 
amoxycillin/clavulanic acid were reported by Lode et 
al in patients with non-severe, mild-to-moderate 
CAP [36]. However, the same mortality rate of 0.4% 
was reported by Carbon et al in a study comparing 
temafloxacin with amoxycillin in patients with CAP of 
average severity [38]. 
In conclusion, the results show that levofloxacin 
was as effective, safe and well tolerated as amoxycillin/ 
clavulanic acid three times daily in the treatment of 
mild-to-moderate CAP. In addition, levofloxacin 
provides the advantage of once-daily dosing. Thus, 
levofloxacin 500 mg once daily, for 7-10 days, is an 
effective and safe treatment for mild-to-moderate CAP 
in adults. 
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